Form 4: Aerovate Therapeutics CEO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Aerovate Therapeutics CEO Timothy P. Noyes exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 16, 2024, Timothy P. Noyes, CEO of Aerovate Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $2.14 per share.
- Simultaneously, Noyes sold 4,491 shares at a weighted average price of $24.3956 and 5,509 shares at a weighted average price of $24.9428.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on November 27, 2023.
- Following these transactions, Noyes directly owns 0 shares of common stock and 363,381 stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports routine transactions under a pre-arranged trading plan. There's no indication of positive or negative news about the company.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the amounts are very large relative to the company's market capitalization.
Key Dates
| Date | Description |
|---|---|
| April 2, 2021 | Grant date of employee stock option for 493,381 shares. |
| June 4, 2022 | 25% of employee stock options vested. |
| November 27, 2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan. |
| April 16, 2024 | Date of the reported transactions: exercising options and selling shares. |
| April 18, 2024 | Date of signature of the Form 4 filing. |
| April 1, 2031 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.